FrancophonIA/ELRC3.0 huggingface dataset:
English: Due to the plasma expanding properties of Oxyglobin, the possibility of circulatory overload and pulmonary oedema should be considered especially when administering adjunctive intravenous fluids, particularly colloidal solutions.
Estonian: Tulenevalt oksüglobiini kui organismi vereplasma koguse suurendaja omadustest peaks eriti silmas pidama tsirkulatoorse ülekoormuse ja kopsuödeemi tekke võimalust veenisiseste vedelike, eeskätt aga kolloidlahuste manustamisel.
English: Oxyglobin 130 mg/ml solution for infusion for dogs
Estonian: Oksüglobiin 130 mg/ml süstelahus koertele
English: Due to the plasma expanding properties of Oxyglobin, the possibility of circulatory overload should be considered especially when administering adjunctive intravenous fluids, particularly colloidal solutions.
Estonian: Oksüglobiini kui vereplasma koguse suurendaja omadustest lähtudes tuleb eriti silmas pidada vereringe ületalitluse tekkimise võimalust veenisiseste vedelike, eriti aga kolloidlahuste samaaegsel manustamisel.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
Estonian: VÄLISPAKENDIL VÕI SELLE PUUDUMISEL SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED
English: A commonly observed undesirable effect was circulatory overload with associated clinical signs such as tachypnea, dyspnea, harsh lung sounds and pulmonary oedema.
Estonian: Sagedasim kõrvaltoime on tsirkulatoorne ülekoormus koos kaasnevate kliiniliste nähtudega nagu tahhüpnoe, düspnoe, räginad kopsudes ja kopsuödeem.
English: Occasionally noted effects were diarrhoea, discolouration of the skin, cardiac arrhythmias and very rarely nystagmus.
Estonian: Mõnedel juhtudel täheldati kõrvaltoimetena diarröad, naha värvuse muutust, südame arütmiat ning üliharva nüstagmust.
English: Treatment with Oxyglobin results in a mild decrease in PCV (packed cell volume) immediately post infusion.
Estonian: Oksüglobiinravi võib põhjustada hematokriti kerget langust vahetult süstimise järel.
English: Solution for infusion.
Estonian: Infusioonilahus
English: NaOH
Estonian: NACl
English: 5.2 Pharmacokinetic particulars
Estonian: Farmakokineetilised andmed
English: Occasionally noted adverse events were diarrhoea, cardiac arrhythmias and very rarely nystagmus.
Estonian: Harvem esinevate kõrvaltoimetena on täheldatud diarröad, südame arütmiat ja väga harva nüstagmust.
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients
Estonian: FARMATSEUTILISED ANDMED 6.1.
English: MARKETING AUTHORISATION NUMBER
Estonian: MÜÜGILOA HOIDJA NIMI
English: ADVERSE REACTIONS
Estonian: Erihoiatused
English: Oxyglobin is intended for single administration.
Estonian: Oksüglobiin on ette nähtud üks kord manustamiseks.
English: Side effects which were observed included mild to moderate discolouration of the mucous membranes, sclera, and urine due to metabolism and/or excretion of haemoglobin.
Estonian: Kõrvaltoimetena esines hemoglobiini metabolismist ja/või eritumisest tingitud mõõdukas limaskestade, skleera ja uriini värvuse muutus.
English: D. STATEMENT OF THE MRLs
Estonian: D. RAVIMJÄÄKIDE PIIRNORMID
English: Do not overheat.
Estonian: Mitte preparaati liigselt soojendada.
English: Name and address of the manufacturer of the biological active substance OPK Biotech LLC
Estonian: Bioloogilise toimeaine tootja nimi ja aadress
English: WITHDRAWAL PERIOD(S)
Estonian: TOIMEAINE(TE) SISALDUS
English: STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
Estonian: TOIMEAINE(D) JA MUUD ABIAINE(D)
English: The capsules should be given with food at around the same time each day.
Estonian: Kapsleid võetakse koos toiduga iga päev ligikaudu samal kellaajal.
English: What measures are being taken to ensure the safe and effective use of Ibrance?
Estonian: Mis meetmeid võetakse, et tagada Ibrance ohutu ja efektiivne kasutamine?
English: Ibrance is available as capsules (75 mg, 100 mg and 125 mg).
Estonian: Ibrancet turustatakse kapslitena (75 mg, 100 mg ja 125 mg).
English: The full EPAR for Ibrance can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Ibrance kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Treatment should continue for as long as the patient is benefitting from it and side effects are tolerable.
Estonian: Ravi tuleb jätkata seni, kuni ravi on patsiendile kasulik ja kõrvalnähud on talutavad.
English: The recommended dose is 125 mg once a day for 21 consecutive days, followed by a 7-day break to complete a 28-day treatment cycle.
Estonian: Soovitatav annus on 125 mg üks kord ööpäevas 21 päeva järjest, millele järgneb 7-päevane ravipaus, mis koos moodustavad 28-päevase ravitsükli.
English: Other information about Ibrance
Estonian: Muu teave Ibrance kohta
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Ibrance's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Ibrance kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Regarding safety, the main risk is neutropenia, which is a well-known risk of many cancer medicines and is considered manageable.
Estonian: Peamine ohutusrisk on neutropeenia, mis on paljude vähiravimite hästi teadaolev risk ja mida peetakse talutavaks.
English: In both studies, the main measure of effectiveness was how long patients lived without their disease getting worse (progression-free survival).
Estonian: Mõlemas uuringus oli efektiivsuse põhinäitaja progresseerumiseta elumus (kui kaua patsiendid elasid haiguse süvenemiseta).
English: If the patient experiences certain side effects, treatment may need to be interrupted or stopped, or the dose reduced.
Estonian: Teatud kõrvalnähtude tekkimisel võib olla vaja ravi katkestada või peatada või annust vähendada.
English: Why is Ibrance approved?
Estonian: Miks Ibrance heaks kiideti?
English: What is Ibrance and what is it used for?
Estonian: Mis on Ibrance ja milleks seda kasutatakse?
English: Ibrance is used in the following ways:
Estonian: Ibrancet kasutatakse koos järgmiste ravimitega:
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ibrance have been included in the summary of product characteristics and the package leaflet.
Estonian: Ibrance ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: • together with an aromatase inhibitor (a hormonal medicine for cancer);
Estonian: • koos aromataasiinhibiitoriga (teatud vähivastane hormoonravim);
English: This is a summary of the European public assessment report (EPAR) for Ibrance.
Estonian: See on ravimi Ibrance Euroopa avaliku hindamisaruande kokkuvõte.
English: It is not intended to provide practical advice on how to use Ibrance.
Estonian: Hindamisaruandes ei anta Ibrance kasutamise praktilisi nõuandeid.
English: • together with fulvestrant (another hormonal medicine for cancer) in patients who have previously been treated with a hormonal medicine.
Estonian: • koos fulvestrandiga (samuti vähivastane hormoonravim) patsientidel, keda on varem ravitud hormoonravimiga.
English: The most common severe side effects with Ibrance (which may affect up to 1 in 50 people) are neutropenia, leucopenia, anaemia, tiredness and infections.
Estonian: Ibrance kõige sagedamad rasked kõrvalnähud (võivad esineda kuni 1 patsiendil 50st) on neutropeenia, leukopeenia, aneemia, väsimus ja infektsioonid.
English: What are the risks associated with Ibrance?
Estonian: Mis riskid Ibrancega kaasnevad?
English: Ibrance can only be used when the cancer cells have receptors for certain hormones on their surface (HR-positive) and do not produce abnormally large quantities of a receptor called HER2 (HER [human epidermal growth factor] negative).
Estonian: Ibrancet tohib kasutada ainult siis, kui vähirakkude pinnal on teatud hormoonide retseptorid (vähirakud on HR-positiivsed) ja kui vähirakud ei tekita ebanormaalselt suures koguses retseptorit HER2 (inimese epidermaalne kasvufaktor 2; vähirakud on HER2-negatiivsed).
English: Ibrance has been shown to prolong the time patients live without their disease getting worse by an average of 6 to 10 months, which is considered of clear clinical value.
Estonian: Ibrance kasutamisel pikenes patsientide progresseerumiseta elumus keskmiselt 6-10 kuu võrra, mis on selge kliiniline kasulikkus.
English: The first study involved 521 women with metastatic breast cancer that had got worse after treatment with a hormonal medicine.
Estonian: Esimeses uuringus osales 521 naist, kellel oli metastaatiline rinnavähk, mis süvenes hormoonravi ajal.
English: Ibrance has been studied in two main studies of women with HR-positive, HER2-negative breast cancer.
Estonian: Ibrancet uuriti HR-positiivse ja HER2-negatiivse rinnavähiga naistel kahes põhiuuringus.
English: In women who have not yet reached menopause, a medicine called a luteinising hormone-releasing hormone agonist should also be given.
Estonian: Menopausieelses eas naised peavad lisaks kasutama luteiniseerivat hormooni vabastava hormooni agonisti.
English: The most common side effects with Ibrance (which may affect more than 1 in 5 people) are neutropenia (low blood levels of neutrophils, a type of white blood cell that fights infection), infections, leucopenia (low white blood cell counts), tiredness, nausea (feeling sick), stomatitis (inflammation of the lining of the mouth), anaemia (low red blood cell counts), alopecia (hair loss) and diarrhoea.
Estonian: Ibrance kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on neutropeenia (nakkusevastaste valgeliblede neutrofiilide vähesus), infektsioonid (nakkused), leukopeenia (leukotsüütide ehk vere valgeliblede vähesus), väsimus, iiveldus, stomatiit (suulimaskesta põletik), aneemia (erütrotsüütide ehk vere punaliblede vähesus), alopeetsia (juuste väljalangemine) ja kõhulahtisus.
English: Ibrance can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
Estonian: Ravi peab alustama ja jälgima ainult vähiravimite kasutamises kogenud arst.
English: Ibrance palbociclib
Estonian: Ibrance palbotsikliib
English: Ibrance contains the active substance palbociclib.
Estonian: Ibrance sisaldab toimeainena palbotsikliibi.
English: For the full list of all side effects reported with Ibrance, see the package leaflet.
Estonian: Ibrance kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How is Ibrance used?
Estonian: Kuidas Ibrancet kasutatakse?
English: They received either Ibrance and letrozole (an aromatase inhibitor) or placebo and letrozole.
Estonian: Uuringus kasutasid patsiendid kas Ibrancet ja letrosooli (teatud aromataasiinhibiitor) või platseebot ja letrosooli.
English: For practical information about using Ibrance, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Ibrance kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The second study involved 666 women who had been through the menopause and whose breast cancer had started to spread and who had not yet received cancer treatment.
Estonian: Teises uuringus osales metastaatilise rinnavähiga 666 menopausijärgses eas naist, kes veel ei olnud saanud muud vähiravi.
English: For more information about treatment with Ibrance, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Ibrancega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: By blocking CDK4 and CDK6, Ibrance slows the growth of HRpositive breast cancer cells.
Estonian: Ibrance blokeerib CDK4 ja CDK6, aeglustades HR-positiivsete rinnavähirakkude kasvu.
English: In some cancers, including HR-positive breast cancer, the activity of CDK 4 and 6 is increased, which helps the cancer cells to multiply uncontrollably.
Estonian: Mõne vähitüübi, sealhulgas HR-positiivse rinnavähi korral on CDK4 ja CDK6 aktiivsus suurenenud, mis aitab vähirakkudel vohada.
English: The active substance in Ibrance, palbociclib, blocks the activity of enzymes known as cyclin-dependent kinases (CDK) 4 and 6, which play a key role in regulating the way cells grow and divide.
Estonian: Ibrance toimeaine palbotsikliib blokeerib rakkude kasvamise ja jagunemise reguleerimisel kõige tähtsamate ensüümide - tsükliinsõltuvate kinaaside (CDK) 4 ja 6 - toime.
English: How does Ibrance work?
Estonian: Kuidas Ibrance toimib?
English: What benefits of Ibrance have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ibrance kasulikkus?
English: Women taking Ibrance and letrozole lived on average 24.8 months without their disease getting worse compared with 14.5 months for women taking placebo and letrozole.
Estonian: Keskmine progresseerumiseta elumus Imbrance ja letrosooli uuringurühmas oli 24,8 kuud ning platseebo ja letrosooli rühmas 14,5 kuud.
English: Ibrance is a cancer medicine used to treat locally advanced or metastatic breast cancer (cancer that has begun to spread to other parts of the body).
Estonian: Ibrance on vähiravim, mida kasutatakse paikselt kaugelearenenud või metastaatilise rinnavähi raviks.
English: Women taking Ibrance and fulvestrant lived on average 11.2 months without their disease getting worse compared with 4.6 months for women taking placebo and fulvestrant.
Estonian: Keskmine progresseerumiseta elumus Imbrance ja fulvestrandi uuringurühmas oli 11,2 kuud ning platseebo ja fulvestrandi uuringurühmas 4,6 kuud.
English: Ibrance must not be used by patients who are taking St John's wort (a herbal preparation used to treat depression).
Estonian: Ibrancet ei tohi kasutada koos naistepunaga (taimne depressiooniravim).
English: International non-proprietary name (INN): lenalidomide
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): lenalidomide
English: The company withdrew its application before the European Commission had adopted a formal decision.
Estonian: Ettevõte võttis taotluse tagasi enne seda, kui Euroopa Komisjon võttis vastu ametliku otsuse.
English: This means that it affects the activity of the immune system (the body's natural defences).
Estonian: See tähendab, et see mõjutab immuunsüsteemi (keha loomuliku kaitsemehhanismi) toimimist.
English: The balance of benefits and risks for Revlimid remains unchanged.
Estonian: Revlimidi riski ja kasulikkuse suhe jääb muutumatuks.
English: Ref. EMEA/294089/2008
Estonian: London, 26. juuni 2008 Viide: EMEA/391218/2008
English: The evaluation had finished and the CHMP had given a negative opinion, which had been confirmed following a re-examination procedure.
Estonian: Hindamine oli lõppenud ja inimravimite komitee oli andnud negatiivse arvamuse, mida kinnitas ka uuesti läbivaatamise menetlus.
English: In addition, an inspection of one of the sites where the main study was carried out raised some concerns over the way the results were recorded, which could have further affected the reliability of the main study.
Estonian: Lisaks muutis ühe põhiuuringu läbiviimise koha kontroll küsitavaks tulemuste kogumise viisi, mis võib veelgi mõjutada põhiuuringu usaldusväärsust.
English: The letter from the company notifying the EMEA of the withdrawal of the application is available here.
Estonian: Ettevõtte kiri, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, on avaldatud siin..
English: Its effectiveness was studied in one main study, carried out in a number of hospitals and clinics (‘sites') in the United States of America and Germany.
Estonian: Ravimi tõhusust uuriti ühes põhiuuringus, mis viidi läbi Ameerika Ühendriikide ja Saksamaa haiglates ja kliinikutes.
English: The main measure of effectiveness was the proportion of patients who became ‘transfusion independent', meaning that their anaemia was controlled without the need for a blood transfusion over an eight-week period.
Estonian: Peamiseks tõhususe näitajaks oli nende patsientide arv, kes muutusid vereülekandest sõltumatuks st kelle aneemia allus kontrollile ilma vajaduseta vereülekandeks kaheksa nädala jooksul.
English: In particular, because the study did not compare the medicine to any other treatment, it was difficult to determine if treatment with Lenalidomide Celgene Europe increased the risk of progression to acute myeloid leukaemia.
Estonian: Eelkõige seetõttu, et uuringus ei võrreldud ravimit ühegi muu ravimiga, on raske määratleda, kas ravi ravimiga Lenalidomide Celgene Europe suurendas ägedaks müeloidleukeemiaks progreseerumise riske.
English: The study looked at the effects of treatment with a daily dose of 10 mg Lenalidomide Celgene Europe either given continuously or as a repeated cycle of three weeks on treatment followed by one week off.
Estonian: Uuringus vaadeldi ravi tõhusust päevase annusega 10 mg ravimit Lenalidomide Celgene Europe annustatuna pidevalt või korduva tsüklina: ravimit manustatakse kolme nädala jooksul, millele järgneb ühenädalane paus.
English: The study involved 148 patients with transfusion-dependent anaemia, low or intermediate (level 1) risk myelodysplastic syndromes and a deletion of part of chromosome 5 (‘5q deletion').
Estonian: Uuringus osales 148 vereülekannet vajava aneemiaga, madala või keskmise (1. tase) riskitaseme müelodüsplastilise sündroomiga ning 5. kromosoomi teatud lõigu deletsiooniga (5q deletsioon) patsienti.
English: Lenalidomide has been authorised in the European Union since June 2007 under the name Revlimid, for the treatment of multiple myeloma.
Estonian: Lenalidomiid on Euroopa Liidus olnud Revlimidi nime all hulgimüeloomi raviks heaks kiidetud alates 2007. aasta juunist.
English: The company informed the CHMP that it will continue to make lenalidomide available for patients included in clinical trials or compassionate use programmes.
Estonian: Ettevõte teatas inimravimite komiteele, et lenalidomiid on jätkuvalt kättesaadav patsientidele, kes osalevad kliinilistes uuringutes või eriloaga kasutamise programmides.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had given a negative opinion and did not recommend a marketing authorisation for Lenalidomide Celgene Europe for the for the treatment of anaemia due to myelodysplastic syndromes.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, oli komitee andnud taotluse tagasivõtmise ajal negatiivse arvamuse ega soovitanud anda ravimile Lenalidomide Celgene Europe müelodüsplastiliste sündroomide põhjustatud aneemia ravis kasutamiseks müügiluba.
English: The exact way that lenalidomide works in myelodysplastic syndromes is not known, but it is thought that it blocks the growth of tumour cells in the bone marrow, while allowing the growth of normal bone marrow cells, including the cells that produce red blood cells.
Estonian: Lenalidomiidi toimemehhanism müelodüsplastilise sündroomi puhul ei ole täielikult teada, kuid arvatakse, et see pärsib kasvajarakkude kasvu luuüdis, pärssimata seejuures normaalsete luuüdi rakkude ning punaliblesid tootvate rakkude kasvu.
English: On 30 May 2008, Celgene Europe Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Lenalidomide Celgene Europe, for the treatment of anaemia due to myelodysplastic syndromes.
Estonian: 30. mail 2008 teatas Celgene Europe Limited ametlikult inimravimite komiteele oma soovist võtta tagasi müelodüsplastilise sündroomi põhjustatud aneemia raviks kavandatud ravimi Lenalidomide Celgene Europe müügiloa taotlus.
English: In some cases, myelodysplastic syndromes can lead to the development of acute myeloid leukaemia (a type of cancer affecting the white blood cells).
Estonian: Mõnel juhul võib müelodüsplastiline sündroom põhjustada ägedat müeloidleukeemiat (valgeid vereliblesid kahjustava vähi liik).
English: Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Lenalidomide Celgene Europe had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
Estonian: Inimravimite komitee oli tagasivõtmise ajal seepärast arvamusel, et ravimi Lenalidomide Celgene Europe kasulikkus ei ole küllaldaselt tõendatud ega ületa tuvastatud riske.
English: Lenalidomide Celgene Europe is a medicine containing the active substance lenalidomide.
Estonian: Lenalidomide Celgene Europe on ravim, mis sisaldab toimeainena lenalidomiidi.
English: There are no consequences of this withdrawal on the use of Revlimid, which also contains lenalidomide, in its authorised indication.
Estonian: Tagasivõtmisel ei ole tagajärgi samuti lenalidomiidi sisaldava Revlimidi kasutamisel nende näidustuste raviks, millele kohta on müügiluba juba antud.
English: What is Lenalidomide Celgene Europe?
Estonian: Mis on Lenalidomide Celgene Europe?
English: Lenalidomide Celgene Europe was designated as an orphan medicinal product on 8 March 2004.
Estonian: Ravim Lenalidomide Celgene Europe nimetati harva kasutatavaks ravimiks 8. märtsil 2004.
English: Multiple myeloma is a cancer of the plasma cells in the bone marrow.
Estonian: Hulgimüeloom on luuüdi plasmarakkude vähk.
English: The CHMP had concerns over the way the main study was carried out, which meant that the safety of Lenalidomide Celgene Europe was difficult to assess.
Estonian: Inimravimite komitee arvas, et teostatud põhiuuringu põhjal on raske hinnata ravimi Lenalidomide Celgene Europe ohutust.
English: Lenalidomide Celgene Europe was to be used in patients who were dependent on receiving blood transfusions to treat their anaemia and whose myelodysplastic syndromes were associated with a specific genetic mutation (deletion of part of chromosome number 5), and with a low to intermediate risk of progressing to leukaemia or death.
Estonian: Ravimit Lenalidomide Celgene Europe kavatseti kasutada patsientidel, kes vajavad aneemia raviks vereülekannet ja kelle müelodüsplastiline sündroom kaasneb teatud geenimutatsiooniga (5. kromosoomi teatud lõigu deletsioon) ning patsientidel, kelle haiguse puhul on madal või keskmine leukeemiaks progresseerumise või surma risk.
English: The active substance in Lenalidomide Celgene Europe, lenalidomide, is an immunomodulating agent.
Estonian: Ravimis Lenalidomide Celgene Europe toimeainena sisalduv lenalidomiid on immuunsust moduleeriv aine.
English: What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Lenalidomide Celgene Europe?
Estonian: Kuidas mõjutab taotluse tagasivõtmine praegu ravimit Lenalidomide Celgene Europe kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
English: Lenalidomide Celgene Europe was expected to be used to treat anaemia (low red blood cell counts) caused by myelodysplastic syndromes, a group of conditions where too few blood cells are produced by the bone marrow.
Estonian: Ravimit Lenalidomide Celgene Europe kavatseti kasutada müelodüsplastilise sündroomi (luuüdi ei tooda piisaval hulgal vererakke) põhjustatud aneemia (punaliblede vähesus) raviks.
English: The effects of Lenalidomide Celgene Europe were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti ravimi Lenalidomide Celgene Europe toimet muude katsetega.
English: What was Lenalidomide Celgene Europe expected to be used for?
Estonian: Milline oli ravimi Lenalidomide Celgene Europe eeldatav toime?
English: QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for LENALIDOMIDE CELGENE EUROPE
Estonian: TEAVE MÜÜGILOA TAOTLUSE TAGASIVÕTMISE KOHTA
English: What is happening with Revlimid used for the treatment of multiple myeloma?
Estonian: Kuidas mõjutab taotluse tagasivõtmine ravimi Lenalidomide Celgene Europe kasutamist hulgimüeloomi raviks?